Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

2(25%)

Results Posted

75%(3 trials)

Terminated

1(13%)

Phase Distribution

Ph phase_2

63%

Ph phase_4

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 2Efficacy & side effects

5(71.4%)

Phase 4Post-market surveillance

2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(4)

Terminated(2)

Detailed Status

Completed4

Terminated1

Withdrawn1

Active, not recruiting1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 4

Trials by Phase

Phase 25 (71.4%)

Phase 42 (28.6%)

Trials by Status

terminated113%

withdrawn113%

active_not_recruiting113%

recruiting113%

completed450%

Recent Activity

2 active trials

Showing 5 of 8

completedphase_2

Clinical Trials (8)

Showing 8 of 8 trials

NCT05430152Phase 2

Low-dose Naltrexone for Post-COVID Fatigue Syndrome

Completed

NCT06366724Phase 2

LIFT: Life Improvement Trial

Recruiting

NCT04313972Phase 4

IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone

Terminated

NCT05307627

The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging

Withdrawn

NCT04739995Phase 4

Cost-utility and Physiological Effects of LDN in Patients With Fibromyalgia

Active Not Recruiting

NCT04052139Phase 2

St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin

Completed

NCT04409041Phase 2

Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia

Completed

NCT04502251Phase 2

LDN and tDCS in Fibromyalgia

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8